algorithm; cost-effectiveness; external quality assessment; frequency; genetic testing; genetics; health informatics; human genetics; medical informatics; proficiency testing; public health; quality control; rare diseases; surveillance, public health authorities
Abstract :
[en] BACKGROUND: Participation in quality controls, also called external quality assessment (EQA) schemes, is required for the ISO15189 accreditation of the Medical Centers of Human Genetics. However, directives on the minimal frequency of participation in genetic quality control schemes are lacking or too heterogeneous, with a possible impact on health care quality. OBJECTIVE: The aim of this project is to develop Belgian guidelines on the frequency of participation in quality controls for genetic testing in the context of rare diseases. METHODS: A group of experts analyzed 90 EQA schemes offered by accredited providers and focused on analyses used for the diagnosis of rare diseases. On that basis, the experts developed practical recommendations about the minimal frequencies of participation of the Medical Centers of Human Genetics in quality controls and how to deal with poor performances and change management. These guidelines were submitted to the Belgian Accreditation Body and then reviewed and approved by the Belgian College of Human Genetics and Rare Diseases and by the National Institute for Health and Disability Insurance. RESULTS: The guidelines offer a decisional algorithm for the minimal frequency of participation in human genetics EQA schemes. This algorithm has been developed taking into account the scopes of the EQA schemes, the levels of experience, and the annual volumes of the Centers of Human Genetics in the performance of the tests considered. They include three key principles: (1) the recommended annual assessment of all genetic techniques and technological platforms, if possible through EQAs covering the technique, genotyping, and clinical interpretation; (2) the triennial assessment of the genotyping and interpretation of specific germline mutations and pharmacogenomics analyses; and (3) the documentation of actions undertaken in the case of poor performances and the participation to quality control the following year. The use of a Bayesian statistical model has been proposed to help the Centers of Human Genetics to determine the theoretical number of tests that should be annually performed to achieve a certain threshold of performance (eg, a maximal error rate of 1%). Besides, the guidelines insist on the role and responsibility of the national public health authorities in the follow-up of the quality of analyses performed by the Medical Centers of Human Genetics and in demonstrating the cost-effectiveness and rationalization of participation frequency in these quality controls. CONCLUSIONS: These guidelines have been developed based on the analysis of a large panel of EQA schemes and data collected from the Belgian Medical Centers of Human Genetics. They are applicable to other countries and will facilitate and improve the quality management and financing systems of the Medical Centers of Human Genetics.
Disciplines :
Genetics & genetic processes
Author, co-author :
Lantoine, Joséphine
Brysse, Anne ; Centre Hospitalier Universitaire de Liège - CHU > Unilab > Discipline génétique
DIDEBERG, Vinciane ; Centre Hospitalier Universitaire de Liège - CHU > Unilab > Laboratoire génétique moléculaire
Evangelista T, Hedley V, Atalaia A, Johnson M, Lynn S, Le Cam Y, et al. The context for the thematic grouping of rare diseases to facilitate the establishment of European Reference Networks. Orphanet J Rare Dis 2016 Feb 24;11:17 [FREE Full _text] [doi: 10.1186/s13023-016-0398-y] [Medline: 26911987]
Bavisetty S, Grody WW, Yazdani S. Emergence of pediatric rare diseases: review of present policies and opportunities for improvement. Rare Dis 2013;1:e23579 [FREE Full _text] [doi: 10.4161/rdis.23579] [Medline: 25002987]
Mazzucato M, Visonà Dalla Pozza L, Minichiello C, Manea S, Barbieri S, Toto E, et al. The epidemiology of transition into adulthood of rare diseases patients: results from a population-based registry. Int J Environ Res Public Health 2018 Oct 10;15(10):2212 [FREE Full _text] [doi: 10.3390/ijerph15102212] [Medline: 30309015]
Boycott KM, Rath A, Chong JX, Hartley T, Alkuraya FS, Baynam G, et al. International cooperation to enable the diagnosis of all rare genetic diseases. Am J Hum Genet 2017 May 04;100(5):695-705 [FREE Full _text] [doi: 10.1016/j.ajhg.2017.04.003] [Medline: 28475856]
Gainotti S, Mascalzoni D, Bros-Facer V, Petrini C, Floridia G, Roos M, et al. Meeting patients' right to the correct diagnosis: ongoing international initiatives on undiagnosed rare diseases and ethical and social issues. Int J Environ Res Public Health 2018 Sep 21;15(10):2072 [FREE Full _text] [doi: 10.3390/ijerph15102072] [Medline: 30248891]
Dharssi S, Wong-Rieger D, Harold M, Terry S. Review of 11 national policies for rare diseases in the context of key patient needs. Orphanet J Rare Dis 2017 Mar 31;12(1):63 [FREE Full _text] [doi: 10.1186/s13023-017-0618-0] [Medline: 28359278]
Berwouts S, Fanning K, Morris MA, Barton DE, Dequeker E. Quality assurance practices in Europe: a survey of molecular genetic testing laboratories. Eur J Hum Genet 2012 Nov;20(11):1118-1126 [FREE Full _text] [doi: 10.1038/ejhg.2012.125] [Medline: 22739339]
Content sheet 10-1: overview of External Quality Assessment (EQA). World Health Organization. 2011 Jan 01. URL: https://terrance.who.int/mediacentre/data/ebola/training-packages/LQMS/10_b_eqa_contents.pdf [accessed 2021-06-16]
Alkhenizan A, Shaw C. Impact of accreditation on the quality of healthcare services: a systematic review of the literature. Ann Saudi Med 2011;31(4):407-416 [FREE Full _text] [doi: 10.4103/0256-4947.83204] [Medline: 21808119]
Cassiman J. Can (should) molecular diagnostic labs improve the quality of their services? Eur J Hum Genet 2012 Nov;20(11):1103-1104 [FREE Full _text] [doi: 10.1038/ejhg.2012.126] [Medline: 22739345]
Tembuyser L, Tack V, Zwaenepoel K, Pauwels P, Miller K, Bubendorf L, et al. The relevance of external quality assessment for molecular testing for ALK positive non-small cell lung cancer: results from two pilot rounds show room for optimization. PLoS One 2014;9(11):e112159 [FREE Full _text] [doi: 10.1371/journal.pone.0112159] [Medline: 25386659]
Claustres M, Kožich V, Dequeker E, Fowler B, Hehir-Kwa JY, Miller K, European Society of Human Genetics. Recommendations for reporting results of diagnostic genetic testing (biochemical, cytogenetic and molecular genetic). Eur J Hum Genet 2014 Feb;22(2):160-170 [FREE Full _text] [doi: 10.1038/ejhg.2013.125] [Medline: 23942201]
ISO 15189:2012 Laboratoires de biologie médicale — Exigences concernant la qualité et la compétence. International Organization for Standardization. 2012 Nov. URL: http://www.iso.org/iso/fr/catalogue_detail?csnumber=56115 [accessed 2020-10-22]
ILAC policy for participation in proficiency testing activities. International Laboratory Accreditation Cooperation. 2014 Jun. URL: https://ilac.org/latest_ilac_news/ilac-p9062014-published/ [accessed 2020-10-22]
Dequeker E. Quality assurance in genetic laboratories. In: Patrinos GP, editor. Molecular Diagnostics. Amsterdam, Netherlands: Elsevier Ltd; 2017:493-500.
Tack V, Ligtenberg MJL, Siebers AG, Rombout PDM, Dabir PD, Weren RDA, et al. RAS testing for colorectal cancer patients is reliable in European laboratories that pass external quality assessment. Virchows Arch 2018 May;472(5):717-725. [doi: 10.1007/s00428-017-2291-z] [Medline: 29333594]
Keppens C, Dufraing K, van Krieken HJ, Siebers AG, Kafatos G, Lowe K, et al. European follow-up of incorrect biomarker results for colorectal cancer demonstrates the importance of quality improvement projects. Virchows Arch 2019 Jul;475(1):25-37. [doi: 10.1007/s00428-019-02525-9] [Medline: 30719547]
Keppens C, Tack V, Hart N, Tembuyser L, Ryska A, Pauwels P, EQA assessors expert group. A stitch in time saves nine: external quality assessment rounds demonstrate improved quality of biomarker analysis in lung cancer. Oncotarget 2018 Apr 17;9(29):20524-20538 [FREE Full _text] [doi: 10.18632/oncotarget.24980] [Medline: 29755669]
Cassiman J. EuroGentest NoE, the ESHG, and genetic services. Eur J Hum Genet 2017 Dec;25(s2):S47-S49 [FREE Full text] [doi: 10.1038/ejhg.2017.155] [Medline: 29297885]
Dufraing K, Lierman E, Vankeerberghen A, Franke S, Dequeker E. External quality assessment for molecular diagnostic laboratories in Belgium: can we improve it? Accred Qual Assur 2019 Nov 25;25(1):39-49. [doi: 10.1007/s00769-019-01410-x]
Matthijs G, Limaye N. Belgian Medical Centers for Human Genetics. Belgian Society for Human Genetics. 2021. URL: https://www.beshg.be/partners/centers [accessed 2021-06-16]
Collège belge de Génétique. 2021. URL: https://www.college-genetics.be/ [accessed 2021-06-16]
European Molecular Genetics Quality Network. URL: https://www.emqn.org [accessed 2021-06-16]
Salk JJ, Schmitt MW, Loeb LA. Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations. Nat Rev Genet 2018 May;19(5):269-285 [FREE Full _text] [doi: 10.1038/nrg.2017.117] [Medline: 29576615]
Petrackova A, Vasinek M, Sedlarikova L, Dyskova T, Schneiderova P, Novosad T, et al. Standardization of sequencing coverage depth in NGS: recommendation for detection of clonal and subclonal mutations in cancer diagnostics. Front Oncol 2019;9:851. [doi: 10.3389/fonc.2019.00851] [Medline: 31552176]
Hofgärtner WT, Tait JF. Frequency of problems during clinical molecular-genetic testing. Am J Clin Pathol 1999 Jul;112(1):14-21. [doi: 10.1093/ajcp/112.1.14] [Medline: 10396281]
Ewen KR, Bahlo M, Treloar SA, Levinson DF, Mowry B, Barlow JW, et al. Identification and analysis of error types in high-throughput genotyping. Am J Hum Genet 2000 Sep;67(3):727-736 [FREE Full _text] [doi: 10.1086/303048] [Medline: 10924406]
Bonin A, Bellemain E, Bronken Eidesen P, Pompanon F, Brochmann C, Taberlet P. How to track and assess genotyping errors in population genetics studies. Mol Ecol 2004 Nov;13(11):3261-3273. [doi: 10.1111/j.1365-294X.2004.02346.x] [Medline: 15487987]
Hoffman JI, Amos W. Microsatellite genotyping errors: detection approaches, common sources and consequences for paternal exclusion. Mol Ecol 2005 Feb;14(2):599-612. [doi: 10.1111/j.1365-294X.2004.02419.x] [Medline: 15660949]
Gilles A, Meglécz E, Pech N, Ferreira S, Malausa T, Martin J. Accuracy and quality assessment of 454 GS-FLX Titanium pyrosequencing. BMC Genomics 2011 May 19;12:245 [FREE Full _text] [doi: 10.1186/1471-2164-12-245] [Medline: 21592414]
Roden DM, Wilke RA, Kroemer HK, Stein CM. Pharmacogenomics: the genetics of variable drug responses. Circulation 2011 Apr 19;123(15):1661-1670 [FREE Full _text] [doi: 10.1161/CIRCULATIONAHA.109.914820] [Medline: 21502584]
Biomedical Quality Assurance KU Leuven. Leuven: KU Leuven Biomedical Quality Assurance; 2020. URL: https://eqascheme.org/ [accessed 2021-06-16]
2020 surveys and anatomic pathology education programs. College of American Pathologists. 2020. URL: https://www.cap.org/laboratory-improvement/catalogs-ordering-and-shipping [accessed 2021-06-16]
United Kingdom National External Quality Assessment Service. URL: https://www.ukneqash.org/ [accessed 2021-06-16]
Schellenberg I, Spannagl M, Hunfeld KP. EQAS Program 2021. INSTAND. 2021 Mar 01. URL: https://www.instand-ev.de/en/instand-eqas/eqas-program-2021/ [accessed 2021-06-16]
Ringversuche. Referenzinstitut für Bioanalytik. 2021. URL: https://www.rfb.bio/cgi/surveys [accessed 2021-06-16]
Brookman B, Butler O, Koch M, Noblett T, Örnemark U, Patriarca M, et al. Proficiency testing in analytical chemistry, microbiology and laboratory medicine: discussions on current practice and future directions. Accred Qual Assur 2015 Apr 8;20(4):339-344. [doi: 10.1007/s00769-015-1120-9]
Essais d'aptitude (proficiency testing): lignes directrices en matiere de participation et evaluation des performances dans le cadre des aduits d'accreditation. FPS Economy. Brussels: BELAC; 2011 Feb 01. URL: https://economie.fgov.be/sites/default/files/Files/Publications/files/Belac-FR/2-106-FR.pdf [accessed 2020-10-22]
OECD guidelines for quality assurance in molecular genetic testing. Organisation for Economic Co-operation and Development. Paris: OECD; 2007. URL: http://www.oecd.org/science/emerging-tech/38839788.pdf [accessed 2021-06-16]
EA-4/18 rev.00 – Guidance on the level and frequency of proficiency testing participation. Accredia. 2010 Jun. URL: https://www.accredia.it/en/documento/ea-418-rev-00-guidance-on-the-level-and-frequency-of-proficiency-testing-participation/ [accessed 2021-06-16]
Örnemark U, Fostel H, Straub R, van de Kreeke J. Policies, requirements and surveys concerning frequency for participation in proficiency testing schemes. Accred Qual Assur 2004 Sep 4;9(11-12):729-732. [doi: 10.1007/s00769-004-0858-2]
Vandevelde NM. Strategies to improve the quality of reference networks for rare diseases. Translational Sci Rare Dis 2020 Aug 03;5(1-2):59-79. [doi: 10.3233/trd-190032]
